Skip to main content

Table 1 Baseline characteristics

From: Etoposide-mediated interleukin-8 secretion from bone marrow stromal cells induces hematopoietic stem cell mobilization

Baseline characteristics G-CSF only
(n= 33)
CY+G-CSF
(n= 24)
ETO+G-CSF
(n= 116)
p-value
Median age (in years) (range) 43.0 (17.0–67.0) 46.5 (20.0–62.0) 52 (21.0–65.0) 0.003
Male:female ratio 2.00 2.43 1.23 0.243
Histology,n(%)     0.139
Hodgkin lymphoma 3 (9.1) 4 (16.7) 5 (4.3)  
Non-Hodgkin lymphoma     
B cell 15 (45.5) 14 (58.3) 65 (56.0)  
T cell 15 (45.5) 6 (25.0) 46 (39.7)  
Disease stage,n(%)     0.342
Limited stage (Stage I-II) 8 (24.2) 3 (12.5) 31 (26.7)  
Advanced stage (Stage III-IV) 25 (75.8) 21 (87.5) 85 (73.3)  
Bone marrow involvement at dagnosis,n(%) 5 (15.2) 6 (25.0) 30 (27.5) 0.472
Number of previous chemotherapy treatments (range) 2 (1-3) 2 (1–3) 1 (1-5) 0.139
Disease status before mobilization,n(%)     0.080
Complete remission 12 (36.4) 10 (41.7) 52 (44.8)  
Partial remission 19 (57.6) 12 (50.0) 47 (40.5)  
Dose, total (mg/m2) (range) 3,000 (1,000–3,000) 750 (375–750)
Time from diagnosis to start of mobilization (months) (range) 7.6 (3.7–63.3) 16.6 (0.7-59.9) 6.2 (1.5–148.0) 0.003
Median follow-up duration after mobilization (months) (range) 12.2 (0.1–96.0) 37.8 (0.1–92.6) 13.0 (1.4–76.8)
Transplantation done,n(%) 29 (90.6) 16 (72.7) 112 (96.6)